ALIGN (2025) — Trial Summary
ALIGN (2025): The ALIGN phase 3 trial evaluated atrasentan, a selective endothelin type A receptor antagonist, versus placebo in patients with IgA nephropathy at risk of progressive kidney function loss, building on the earlier phase 2 APPLAUSE-IgAN results.
References
- Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2025;392:544-554.